Related Experiment Video
Updated: Feb 8, 2026

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Comparative Efficacy of Treatments for Previously Treated Advanced or Metastatic Non-Small-Cell Lung Cancer: A
Junlong Li1, Medha Sasane2, Jing Zhao3
1Analysis Group Inc., 111 Huntington Ave, Floor 14, Boston, MA, 02199, USA. junlong.li@analysisgroup.com.
Introduction:
Due to the rarity of BRAF V600E mutation, no randomized study has compared the combination targeted therapy dabrafenib + trametinib with other second-line treatments for advanced or metastatic non-small-cell lung cancer (NSCLC). A network meta-analysis (NMA) was conducted to assess the comparative efficacy of treatments among patients with previously treated advanced or metastatic NSCLC.
Methods:
Randomized trials of dabrafenib + trametinib, docetaxel, erlotinib, nintedanib + docetaxel, nivolumab, pemetrexed, pembrolizumab, and best supportive care as second-line or above treatments for advanced or metastatic NSCLC identified in a systematic literature review were included in the NMA. Overall response rates (ORRs) and disease control rates (DCRs) were compared using logit models; progression-free survival (PFS) and overall survival (OS) were compared using fractional polynomial hazards models. Dabrafenib + trametinib was linked into the evidence network through a matching-adjusted indirect comparison versus nivolumab.
Results:
Ten trials met the inclusion criteria and were included in the NMA. Dabrafenib + trametinib, pembrolizumab, and nivolumab were associated with the highest odds of achieving overall response (12.2, 1.2, and 0.7 times higher, respectively, compared with docetaxel). Estimated DCR was higher for dabrafenib + trametinib, nintedanib + docetaxel, and pemetrexed compared with other treatments. Patients treated with dabrafenib + trametinib, nivolumab, and pembrolizumab had the lowest hazards of disease progression or death during follow-up (72, 61, and 29% lower hazard of progression at 6 months; 61, 48, and 46% lower hazard of death at 1 year, respectively, compared with docetaxel).
Conclusion:
Dabrafenib + trametinib, pembrolizumab, and nivolumab were associated with higher ORR and prolonged PFS and OS compared with chemotherapy in previously treated advanced or metastatic NSCLC.
Funding:
Novartis Pharmaceuticals Corporation.
Insights
The combination targeted therapy dabrafenib plus trametinib, along with immunotherapy agents pembrolizumab and nivolumab, demonstrated superior efficacy compared to chemotherapy for advanced non-small-cell lung cancer (NSCLC) patients in a network meta-analysis.
Area of Science:
- Oncology
- Medical Research
- Pharmacology
Background:
- Advanced or metastatic non-small-cell lung cancer (NSCLC) presents treatment challenges, particularly in the second-line setting.
- The BRAF V600E mutation is rare, precluding randomized trials comparing targeted therapy dabrafenib plus trametinib with other second-line options.
- A comprehensive assessment of comparative treatment efficacy is crucial for optimizing patient outcomes in previously treated advanced NSCLC.
Purpose of the Study:
- To conduct a network meta-analysis (NMA) to compare the efficacy of various second-line treatments for advanced or metastatic NSCLC.
- To evaluate treatments including dabrafenib plus trametinib, chemotherapy agents, immunotherapy, and best supportive care.
- To assess overall response rates (ORR), disease control rates (DCR), progression-free survival (PFS), and overall survival (OS).
Main Methods:
- A systematic literature review identified randomized trials for second-line or later treatments in advanced/metastatic NSCLC.
- Network meta-analysis (NMA) was performed using logit models for ORR/DCR and fractional polynomial hazards models for PFS/OS.
- Dabrafenib plus trametinib was indirectly compared to nivolumab via matching-adjusted indirect comparison.
Main Results:
- Dabrafenib plus trametinib, pembrolizumab, and nivolumab showed significantly higher odds of achieving overall response compared to docetaxel.
- Higher disease control rates were observed for dabrafenib plus trametinib, nintedanib plus docetaxel, and pemetrexed.
- Patients receiving dabrafenib plus trametinib, nivolumab, or pembrolizumab experienced significantly lower hazards of disease progression and death at 6 months and 1 year, respectively, compared to docetaxel.
Conclusions:
- In previously treated advanced or metastatic NSCLC, dabrafenib plus trametinib, pembrolizumab, and nivolumab are associated with improved efficacy.
- These agents demonstrate higher overall response rates and prolonged progression-free and overall survival compared to chemotherapy.
- The findings support the consideration of these targeted and immunotherapy options in the second-line treatment landscape for advanced NSCLC.
More Related Videos
06:49Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
Published on: February 10, 2023
05:36Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
Related Concept Videos
Comparing the Survival Analysis of Two or More Groups
Protein Networks
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
Treatment Resistant Cancers
Sample Preparation for Analysis: Advanced Techniques
Acid digestion with strong acids is commonly used to dissolve inorganic materials that are insoluble (do not dissolve) in water. This method can be useful for...
Lung Capacity
Self-Efficacy